InvestorsHub Logo
Followers 39
Posts 1575
Boards Moderated 0
Alias Born 02/26/2013

Re: None

Friday, 07/12/2013 9:20:39 AM

Friday, July 12, 2013 9:20:39 AM

Post# of 91007
About SVFC's competition:

There are other companies using lipoaspirate tissue to manufacture stromal vascular fraction. Companies, such as Cytori and Celltex, use an enzyme (collagenese) to separate the SVFC's from the blood vessels in the adipose tissue and they are being regulated by FDA as a drug, due to the fact that the use of enzymes causes significant biologic manipulation. Cytori, Celltex, Tissuegenesis, and others are utilizing a point of care device to produce the cellular product. When factoring in the cost of the capital equipment (as much as $70,000 each) and high disposal cost per case (as much as $1,500), IntelliCell believes it has a superior laboratory system and process in place. Further, the point of care systems do not produce industry standard batch manufacturing records demonstrating compliance with Quality Assurance that is standard practice in any cGTP or cGMP facility. Specific cell counts, cell viability,
gram staining, endotoxin testing (all part of IntelliCell SOP's) are not included with the point of care systems.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.